Table 2.

Analysis of remission in patients stratified by historical ANCA status, baseline BVAS, and baseline VDI score

	History of positive ANCA test				Baseline BVAS				Baseline VDI score
	Yes		No		BVAS = 0		BVAS > 0		VDI < 5		VDI ≥ 5
	PBO	Mepo	PBO	Mepo	PBO	Mepo	PBO	Mepo	PBO	Mepo	PBO	Mepo
	(n = 13)	(n = 13)	(n = 55)	(n = 55)	(n = 20)	(n = 31)	(n = 48)	(n = 37)	(n = 36)	(n = 38)	(n = 32)	(n = 30)
Accrued duration of remission a , b (wk), n (%)
0	10 (77)	4 (31)	45 (82)	28 (51)	16 (80)	10 (32)	39 (81)	22 (59)	27 (75)	17 (45)	28 (88)	15 (50)
>0 to <12	2 (15)	0	6 (11)	8 (15)	2 (10)	3 (10)	6 (13)	5 (14)	5 (14)	6 (16)	3 (9)	2 (7)
12 to <24	0	4 (31)	3 (5)	5 (9)	0	8 (26)	3 (6)	1 (3)	2 (6)	6 (16)	1 (3)	3 (10)
24 to <36	0	2 (15)	0	8 (15)	0	3 (10)	0	7 (19)	0	4 (11)	0	6 (20)
≥36	1 (8)	3 (23)	1 (2)	6 (11)	2 (10)	7 (23)	0	2 (5)	2 (6)	5 (13)	0	4 (13)
OR (95% CI) c	21.06 (2.65, 167.18)		4.91 (2.04, 11.81)		6.76 (1.66, 27.60)		3.88 (1.44, 10.51)		4.03 (1.49, 10.87)		24.12 (4.91, 118.50)
Proportion of patients in remission b at Weeks 36 and 48, n (%)	0	7 (54)	2 (4)	15 (27)	1 (5)	14 (45)	1 (2)	8 (22)	2 (6)	11 (29)	0	11 (37)
OR (95% CI) c	NA		9.01 (1.87, 43.43)		13.40 (1.46, 122.82)		15.28 (1.71, 136.57)		5.58 (1.05, 29.61)		NA

Abbreviations: ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; CI, confidence interval; Mepo, mepolizumab; NA, not applicable—estimate could not be calculated owing to lack of patients in the placebo group achieving remission at Weeks 36 and 48; OR, odds ratio; PBO, placebo; VDI, Vasculitis Damage Index.

^a Accrued number of weeks of remission over the 52‐week study period categorized in weeks (0, >0 to <12, 12 to <24, 24 to <36, and ≥36 weeks).

^b Remission was defined as BVAS = 0 and oral glucocorticoid dose ≤4 mg/day of a prednisone equivalent.

^c Mepolizumab versus placebo.